95% Shrinkage of Lung Tumors with This Drug. Should be $20 + ( LINK )
Oncolytics Biotech® Inc. Announces Additional Positive REOLSYIN® Clinical Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung
Press Release: Oncolytics Biotech Inc. – Fri, Feb 8, 2013 6:30 AM EST
CALGARY , Feb. 8, 2013 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (ONC.TO) (ONCY) today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel (REO 021).
The analysis examined percent best overall tumour changes between pre-treatment and up to six treatment cycles. Of 20 evaluable patients, 19 (95%) exhibited overall tumour shrinkage, (mean (20 patients): 33.7% shrinkage).